Cogent Biosciences (COGT) Competitors $12.94 -0.14 (-1.07%) Closing price 09/4/2025 04:00 PM EasternExtended Trading$12.71 -0.23 (-1.78%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock COGT vs. NUVL, MRUS, CRSP, TGTX, CYTK, AAPG, KRYS, ACAD, ADMA, and TLXShould you be buying Cogent Biosciences stock or one of its competitors? The main competitors of Cogent Biosciences include Nuvalent (NUVL), Merus (MRUS), CRISPR Therapeutics (CRSP), TG Therapeutics (TGTX), Cytokinetics (CYTK), Ascentage Pharma Group International (AAPG), Krystal Biotech (KRYS), ACADIA Pharmaceuticals (ACAD), ADMA Biologics (ADMA), and Telix Pharmaceuticals (TLX). These companies are all part of the "pharmaceutical products" industry. Cogent Biosciences vs. Its Competitors Nuvalent Merus CRISPR Therapeutics TG Therapeutics Cytokinetics Ascentage Pharma Group International Krystal Biotech ACADIA Pharmaceuticals ADMA Biologics Telix Pharmaceuticals Nuvalent (NASDAQ:NUVL) and Cogent Biosciences (NASDAQ:COGT) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership. Do institutionals & insiders have more ownership in NUVL or COGT? 97.3% of Nuvalent shares are owned by institutional investors. 10.2% of Nuvalent shares are owned by insiders. Comparatively, 7.3% of Cogent Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Do analysts prefer NUVL or COGT? Nuvalent presently has a consensus price target of $120.91, indicating a potential upside of 51.76%. Cogent Biosciences has a consensus price target of $20.00, indicating a potential upside of 54.56%. Given Cogent Biosciences' higher probable upside, analysts clearly believe Cogent Biosciences is more favorable than Nuvalent.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvalent 0 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 3.08Cogent Biosciences 0 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 2.92 Which has higher earnings & valuation, NUVL or COGT? Nuvalent is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuvalentN/AN/A-$260.76M-$4.90-16.26Cogent BiosciencesN/AN/A-$255.86M-$1.78-7.27 Does the media prefer NUVL or COGT? In the previous week, Nuvalent had 8 more articles in the media than Cogent Biosciences. MarketBeat recorded 17 mentions for Nuvalent and 9 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.30 beat Nuvalent's score of 1.15 indicating that Cogent Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvalent 11 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Cogent Biosciences 9 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is NUVL or COGT more profitable? Nuvalent's return on equity of -32.58% beat Cogent Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets NuvalentN/A -32.58% -30.14% Cogent Biosciences N/A -223.82%-89.44% Which has more risk & volatility, NUVL or COGT? Nuvalent has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500. Comparatively, Cogent Biosciences has a beta of 0.35, indicating that its stock price is 65% less volatile than the S&P 500. SummaryNuvalent beats Cogent Biosciences on 8 of the 14 factors compared between the two stocks. Get Cogent Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for COGT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding COGT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart COGT vs. The Competition Export to ExcelMetricCogent BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.49B$3.13B$5.76B$9.85BDividend YieldN/A2.28%6.67%4.51%P/E Ratio-7.2720.8975.7826.43Price / SalesN/A458.96546.96119.09Price / CashN/A44.5237.0558.92Price / Book9.809.9311.146.06Net Income-$255.86M-$53.38M$3.29B$266.28M7 Day Performance7.12%0.63%0.16%-0.32%1 Month Performance13.91%6.31%6.26%3.44%1 Year Performance15.12%11.63%54.63%23.11% Cogent Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COGTCogent Biosciences3.1644 of 5 stars$12.94-1.1%$20.00+54.6%+12.7%$1.49BN/A-7.2780News CoveragePositive NewsAnalyst ForecastNUVLNuvalent3.2292 of 5 stars$74.05-2.7%$118.91+60.6%-5.8%$5.49BN/A-15.1140Positive NewsAnalyst ForecastMRUSMerus3.0269 of 5 stars$65.74-2.6%$88.64+34.8%+29.2%$5.10B$36.13M-11.9537News CoveragePositive NewsCRSPCRISPR Therapeutics3.5966 of 5 stars$54.13-0.3%$71.60+32.3%+17.1%$4.94B$37.31M-9.97460TGTXTG Therapeutics4.4195 of 5 stars$28.53-3.1%$46.25+62.1%+44.4%$4.67B$329M77.11290Positive NewsCYTKCytokinetics4.1956 of 5 stars$37.01-3.5%$71.58+93.4%-9.4%$4.59B$18.47M-7.26250Trending NewsAnalyst ForecastInsider TradeOptions VolumeAAPGAscentage Pharma Group InternationalN/A$43.48-9.2%N/AN/A$4.45B$134.35M0.00600Positive NewsGap DownHigh Trading VolumeKRYSKrystal Biotech4.8125 of 5 stars$146.77-2.5%$210.38+43.3%-19.5%$4.36B$290.52M29.83210Positive NewsACADACADIA Pharmaceuticals4.0632 of 5 stars$25.32-1.6%$28.88+14.0%+52.8%$4.34B$957.80M19.04510ADMAADMA Biologics3.9415 of 5 stars$17.01-4.4%$27.67+62.6%+0.2%$4.25B$426.45M19.78530Positive NewsTLXTelix PharmaceuticalsN/A$12.20-2.2%$22.33+83.1%N/A$4.22B$516.72M0.00N/AGap Down Related Companies and Tools Related Companies Nuvalent Alternatives Merus Alternatives CRISPR Therapeutics Alternatives TG Therapeutics Alternatives Cytokinetics Alternatives Ascentage Pharma Group International Alternatives Krystal Biotech Alternatives ACADIA Pharmaceuticals Alternatives ADMA Biologics Alternatives Telix Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:COGT) was last updated on 9/5/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cogent Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cogent Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free COGT Stock Alerts